Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.

Autor:	Lazow MA; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Pediatric Neuro-Oncology Program, Nationwide Children's Hospital, Columbus, Ohio, USA.; The Ohio State University College of Medicine, Columbus, Ohio, USA., Fuller C; Department of Pathology, Upstate Medical University, Syracuse, New York, USA., DeWire M; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Lane A; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Bandopadhayay P; Dana Farber Cancer Institute, Harvard Cancer Center, Boston, Massachusetts, USA., Bartels U; Division of Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada., Bouffet E; Division of Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada., Cheng S; Division of Pediatric Hematology/Oncology/BMT, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada., Cohen KJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA., Cooney TM; Dana Farber Cancer Institute, Harvard Cancer Center, Boston, Massachusetts, USA., Coven SL; Division of Oncology, Riley Hospital for Children, Indianapolis, Indiana, USA., Dholaria H; Department of Oncology, Perth Children's Hospital, Nedlands, Australia., Diez B; Department of Oncology and Pathology, Fundacion para la lucha de las enfermedades neurologicas de la infancia FLENI, Buenos Aires, Argentina., Dorris K; Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, Colorado, USA., El-Ayadi M; National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt., El-Sheikh A; Division of Oncology, Dayton Children's Hospital, Dayton, Ohio, USA., Fisher PG; Department of Neurology, Stanford University, Stanford, California, USA., Fonseca A; Division of Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada., Garcia Lombardi M; Division of Oncology, Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina., Greiner RJ; Division of Oncology, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA., Goldman S; Department of Pediatrics, Phoenix Children's Hospital, University of Arizona College of Medicine-Phoenix, Phoenix, Arizona, USA., Gottardo N; Department of Oncology, Perth Children's Hospital, Nedlands, Australia., Gururangan S; Department of Neurosurgery, University of Florida, Gainsville, Florida, USA., Hansford JR; Children's Cancer Centre, Royal Children's Hospital Murdoch Children's Research Institute University of Melbourne, Melbourne, Victoria, Australia., Hassall T; Division of Oncology, Queensland Children's Hospital, South Brisbane, Australia., Hawkins C; Division of Pathology, The Hospital for Sick Children, Toronto, Ontario, Canada., Kilburn L; Division of Oncology, Children's National Medical Center, Washinton, District of Columbia, USA., Koschmann C; Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA., Leary SE; Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, Washington, USA., Ma J; Division of Oncology, Xinhua Hospital, Shanghai, China., Minturn JE; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA., Monje-Deisseroth M; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Packer R; Division of Oncology, Children's National Medical Center, Washinton, District of Columbia, USA., Samson Y; Division of Oncology, CHU Saint Justine, Montreal, Quebec, Canada., Sandler ES; Division of Oncology, Nemours Children's Health System, Wilmington, Delaware, USA., Sevlever G; Department of Oncology and Pathology, Fundacion para la lucha de las enfermedades neurologicas de la infancia FLENI, Buenos Aires, Argentina., Tinkle CL; Division of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA., Tsui K; Division of Oncology, Starship Children's Hospital, Auckland, New Zealand., Wagner LM; Division of Pediatric Hematology/Oncology, University of Kentucky, Lexington, Kentucky, USA., Zaghloul M; National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt., Ziegler DS; School of Women's and Children's Health and Children's Cancer Institute, University of New South Wales, Sydney, Australia., Chaney B; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Black K; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Asher A; Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA., Drissi R; The Ohio State University College of Medicine, Columbus, Ohio, USA.; Center for Childhood Cancer & Blood Disorders, Nationwide Children's Hospital, Columbus, Ohio, USA., Fouladi M; Pediatric Neuro-Oncology Program, Nationwide Children's Hospital, Columbus, Ohio, USA.; The Ohio State University College of Medicine, Columbus, Ohio, USA., Jones BV; Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Leach JL; Department of Radiology and Medical Imaging, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Jazyk:	angličtina
Zdroj:	Neuro-oncology [Neuro Oncol] 2022 May 04; Vol. 24 (5), pp. 821-833.
DOI:	10.1093/neuonc/noab245
Abstrakt:	Background: Diffuse intrinsic pontine glioma (DIPG) remains a clinico-radiologic diagnosis without routine tissue acquisition. Reliable imaging distinction between DIPG and other pontine tumors with potentially more favorable prognoses and treatment considerations is essential. Methods: Cases submitted to the International DIPG registry (IDIPGR) with histopathologic and/or radiologic data were analyzed. Central imaging review was performed on diagnostic brain MRIs (if available) by two neuro-radiologists. Imaging features suggestive of alternative diagnoses included nonpontine origin, <50% pontine involvement, focally exophytic morphology, sharply defined margins, and/or marked diffusion restriction throughout. Results: Among 286 patients with pathology from biopsy and/or autopsy, 23 (8%) had histologic diagnoses inconsistent with DIPG, most commonly nondiffuse low-grade gliomas and embryonal tumors. Among 569 patients with centrally-reviewed diagnostic MRIs, 40 (7%) were classified as non-DIPG, alternative diagnosis suspected. The combined analysis included 151 patients with both histopathology and centrally-reviewed MRI. Of 77 patients with imaging classified as characteristic of DIPG, 76 (99%) had histopathologic diagnoses consistent with DIPG (infiltrating grade II-IV gliomas). Of 57 patients classified as likely DIPG with some unusual imaging features, 55 (96%) had histopathologic diagnoses consistent with DIPG. Of 17 patients with imaging features suggestive of an alternative diagnosis, eight (47%) had histopathologic diagnoses inconsistent with DIPG (remaining patients were excluded due to nonpontine tumor origin). Association between central neuro-imaging review impression and histopathology was significant (p < 0.001), and central neuro-imaging impression was prognostic of overall survival. Conclusions: The accuracy and important role of central neuro-imaging review in confirming the diagnosis of DIPG is demonstrated. (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu